Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• UK MHRA Accepts Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment: Biosplice Therapeutics initiates the formal assessment process for the first potential disease-modifying osteoarthritis drug (DMOAD), offering a pharmacological intervention designed to structurally improve joint space width. Source: GlobeNewswire.
• Publishes New Analyses Reinforcing the Scientific Rationale for PP353 in Vertebrogenic Lumbar Back Pain: Persica Pharmaceuticals data strengthens the case for treating the bacterial component of Modic Type 1 changes, providing a non-surgical, non-opioid pathway for chronic low back pain. Source: GlobeNewswire.
• Mpact 3D Metal Foam Cleared: Medacta International S.A. received FDA clearance (K253630) for Primary and Revision Total Hip Arthroplasty (THA).
• Iconix Knotless T Cleared: Riverpoint Medical received FDA clearance (K262677) for Sports Medicine Soft Tissue-to-Bone Fixation.
• VariLift-C Cervical Interbody Fusion System Cleared: Wenzel Spine, Inc. received FDA clearance (K262595) for Expandable Anterior Cervical Discectomy and Fusion (ACDF).

DAILY ANNOUNCEMENTS BY CATEGORY

Joint Reconstruction & Preservation

Biosplice Therapeutics — UK MHRA Accepts Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment

• Summary: Biosplice Therapeutics announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has formally accepted its regulatory application for lorecivivint (LOR), initiating the formal assessment process for the treatment of knee osteoarthritis. Lorecivivint is a first-in-class small-molecule CLK/DYRK kinase inhibitor administered via intra-articular injection.
• Key Details:
  • Device/System Name: Lorecivivint (LOR)
  • Status: MHRA Regulatory Application Accepted
  • Clinical Significance: If approved, lorecivivint would represent the first disease-modifying osteoarthritis drug (DMOAD) on the market, offering a pharmacological intervention designed to structurally improve joint space width and potentially delay the need for total knee arthroplasty (TKA).
• Original Source: GlobeNewswire

Spine & Orthobiologics

Persica Pharmaceuticals — Publishes New Analyses Reinforcing the Scientific Rationale for PP353 in Vertebrogenic Lumbar Back Pain

• Summary: Persica Pharmaceuticals announced the publication of new clinical analyses highlighting the antibiotic exposure-response relationship of its lead candidate, PP353. The data demonstrates that clinical improvement in patients suffering from chronic vertebrogenic low back pain (cLBP) correlates strongly with intradiscal linezolid exposure levels, confirming the drug's mechanism of action.
• Key Details:
  • Device/System Name: PP353 (Targeted Intradiscal Linezolid)
  • Status: Clinical Data Publication (Phase 1b completed)
  • Clinical Significance: Strengthens the scientific case for treating the underlying bacterial component of Modic Type 1 changes in chronic low back pain, providing a targeted non-surgical, non-opioid therapeutic pathway that may prevent the progression to spinal fusion.
• Original Source: GlobeNewswire

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.